Moderna Stock Crashes on Cancer Vaccine Data Leak Despite Positive Phase 3 Results

What’s happening

Moderna's stock plunged after Phase 3 trial data for its personalized cancer vaccine (developed with Merck) leaked ahead of official release, though the full dataset released later showed positive efficacy signals. The market reaction suggests investors punished the leak itself and questioned whether the results met the bar set by earlier hype.

Market impact

Moderna (MRNA) has been a momentum darling this year; the stock's sharp reversal on positive data signals investor skepticism about valuation and execution risk. The leak also raises governance concerns, potentially inviting regulatory scrutiny and analyst downgrades if the market perceives the data as merely meeting, not exceeding, expectations.

Broader implications

The cancer vaccine represents Moderna's pivot beyond COVID; a stumble here undermines the narrative that the company can diversify revenue streams. Approval is likely, but the market's tepid response suggests investors are pricing in competitive pressure from other cancer immunotherapy players and questions about real-world adoption rates.